153 results
Page 4 of 8
8-K
EX-99.1
51o yck4a
14 Dec 21
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
7:02am
8-K
EX-3.2
kmcxawg d207oqda
8 Nov 21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
7:32am
424B5
aohukbpcct0 awk
11 Aug 21
Prospectus supplement for primary offering
6:56am
8-K
EX-4.1
5s4botlau7mq
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.1
0mh2xomhepigm4s
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-4.2
1ub62lp6nld8vgt0oj
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
424B3
dgs6n pgp
30 Apr 21
Prospectus supplement
5:01pm
8-K
EX-99.1
b97z9fjp952fzxqh7eqi
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-10.2
8ks37
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-4.1
99zipwo6jafj
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-10.1
m697v0aow2
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am